Luca Mazzarella

@matsadoc

Oncologist, clinician scientist, failed drummer, accomplished father

Milano, Lombardia
Vrijeme pridruživanja: studeni 2011.

Medijski sadržaj

  1. 9. stu 2019.

    Guess what? Anti-PDL1 better than chemo in hi PDL1 NSCLC 1st line . Hardly groundbreaking news, will it help bring prices down?

  2. 9. stu 2019.

    Absolutely mindblowing talk by Ron Germain at . Advanced imaging changes understanding of tumor-immune interaction. Never thought that PD1 comes up to slow down T cells!

    Prikaži ovu nit
  3. 17. tra 2018.

    Heating up cold melanomas with a TLR9 agonist. 22% response rate with pembro in PD1 nonresponders

  4. 16. tra 2018.

    Basically, after , when you see a NSCLC at any stage including pre-op, ask yourself if there is any reason NOT to give immumo. Otherwise, go for it! Small study, OS awaited, but impressive data on neoadj by D Pardoll

  5. 16. tra 2018.

    10 muts/Mb SHALL BE your TMB threshold. Almost a Pythagorean beauty in this number, maybe TOO beautiful? Some healthy skepticism by D Rimm (with whom I humbly disagree...)

  6. 16. tra 2018.

    Interesting decision tree for NSCLC after by N Rizvi

  7. 16. tra 2018.

    Guess there is only one reason why we dont routinely use TMB instead of PDL1 to identify pts who benefit from immuno: accessibility to routine NGS. Things MUST change after Checkmate227

  8. 16. tra 2018.

    Now this is interesting. Atezo+beva+CT improves PFS even in EGFR/ALK-mutated NSCLC, for which immuno alone does not work

  9. 16. tra 2018.

    Good to see I and Roy Herbst agree Thanks Roy

  10. 16. tra 2018.

    Booooom guess we have a new standard in nonsquamous NSCLC with pembro+pemetr+platinum

  11. 16. tra 2018.

    A not-so-far future . SIRI, tell me how to treat my patient with multiple obscure mutations, then get me a pizza. Love you Siri

  12. 15. tra 2018.

    Intriguing findings in the TRACERx studies on lung and renal cancers. 1. Frequent HLA LOH in lung allows immune evasion 2. Chromosomal instability mediates metastases, NOT point mutations. Thanks C Swanton

  13. 15. tra 2018.

    George Coukos frustrated by why ovarian cancers respond poorly to PD1 blockade. TILs are neoantigen-specific, PD1 is expressed and active, so why the hell? Endothelium may exclude T cells from the hot area. Bevacizumab+vaccine may sensitize

  14. 15. tra 2018.

    Yet another confirmation that PD1 blockade dramatically reduces recurrences after radical surgery in stage 3 melanoma, with moderate tox. But would survival change if we gave pembro at relapse, not before relapse? Crossover in keynote 054 will tell

  15. 15. tra 2018.

    Time has come for prospective interventional testing of liquid biopsy, says K Pantel . should we change our treatment based on LQ?

  16. 7. ožu 2018.

    Brilliant talk by L Fong on PD1-CTLA4 combo immunotherapy. Maybe 2 is NOT better than 1 in low burden disease because of T cell hyperactivation-induced cell death

  17. 7. ožu 2018.

    Geographical and diet-mediated differences in anti-PD1 nonresponders' gut microbiota! could this lead to geographical differences in IO trials?

  18. 6. ožu 2018.

    New advices from the on the tough topic of conducting combo immune oncology trials at

  19. 31. lis 2017.

    The future of liquid biopsies, with nucleosome mapping and cpg meth. Brilliant talk by M Speicher at

  20. 14. lis 2017.

    Normale sabato sera a ascaniosforza81.Cori da stadio e lancio di bottiglie nel .grazie e ,sto sereno

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·